Page 8 - FLIPBOOK
P. 8
The Prostate Cancer Landscape
Docetaxel
Abiraterone
Enzalutamide
ARAT/CYP17 Inhibitor Radiopharmaceuticals Apalutamide
Chemotherapy PARP inhibitor NEWLY
ADT DIAGNOSED
mHSPC
PRIMARY
PROGRESSIVE
LOCALIZED OR LOCALLY BIOCHEMICAL mHSPC TERMINAL DISEASE
ADVANCED mCRPC
PROSTATE CANCER RECURRENCE (DEATH)
nmCRPC Docetaxel
Cabazitaxel
Enzalutamide
Apalutamide Abiraterone
Darolutamide Enzalutamide
Olaparib
Radium 223
Androgen Deprivation Therapy (ADT) – Foundation of Care (LHRH Agonist or Antagonist)
ARAT Androgen-receptor axis-targeted agents LHRH Luteinizing hormone-releasing hormone
mHSPC Metastatic hormone sensitive prostate cancer
nmCRPC Non-metastatic castration resistant prostate cancer mCRPC Metastatic CRPC
